In addition, other cancers have been observed in carriers, although actionable guidelines for increased surveillance for these cancers are not available at this time (18, 19).The penetrance rate for melanoma in individuals with CDKN2A PVs is estimated at 58-92% by age 80 (13, 20, 21). This evidence concerns the gene CDKN2A and cancer.